Encouraging results but questions remain for dengue vaccine

Affiliations

¹ Global Dengue and Aedes-Transmitted Diseases Consortium, International Vaccine Institute, SNU Research Park, Gwanak-gu 08826, South Korea. Electronic address: inkyu.yoon@ivi.int.
² Upstate Medical University, State University of New York, Syracuse, NY, USA.

Comment

In-Kyu Yoon et al. Lancet Infect Dis. 2018 Feb.

. 2018 Feb;18(2):125-126.

doi: 10.1016/S1473-3099(17)30634-5. Epub 2017 Nov 6.

¹ Global Dengue and Aedes-Transmitted Diseases Consortium, International Vaccine Institute, SNU Research Park, Gwanak-gu 08826, South Korea. Electronic address: inkyu.yoon@ivi.int.
² Upstate Medical University, State University of New York, Syracuse, NY, USA.

No abstract available

Comment on

Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study.
Sáez-Llorens X, Tricou V, Yu D, Rivera L, Jimeno J, Villarreal AC, Dato E, Mazara S, Vargas M, Brose M, Rauscher M, Tuboi S, Borkowski A, Wallace D. Sáez-Llorens X, et al. Lancet Infect Dis. 2018 Feb;18(2):162-170. doi: 10.1016/S1473-3099(17)30632-1. Epub 2017 Nov 6. Lancet Infect Dis. 2018. PMID: 29122463 Clinical Trial.